OncoMed Pharmaceuticals Inc 4
4 · OncoMed Pharmaceuticals Inc · Filed Jan 5, 2017
Insider Transaction Report
Form 4
Hoey Timothy
SVP, Cancer Biology
Transactions
- Sale
Common Stock
2017-01-03$7.64/sh−12,763$97,448→ 60,979 total - Exercise/Conversion
Stock Option (Right to Buy)
2017-01-03−12,763→ 0 totalExercise: $1.43Exp: 2017-01-11→ Common Stock (12,763 underlying) - Exercise/Conversion
Common Stock
2017-01-03$1.43/sh+12,763$18,251→ 73,742 total - Award
Stock Option (Right to Buy)
2017-01-03+55,000→ 55,000 totalExercise: $7.66Exp: 2027-01-02→ Common Stock (55,000 underlying)
Footnotes (5)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 21, 2016.
- [F2]Includes 27,500 restricted stock units. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) restricted stock unit.
- [F3]This transaction was executed in multiple trades in prices ranging from $7.55 to $7.845, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F4]The option is fully vested and exercisable, subject to an annual limitation of 175,438 shares that can be issued to a single grantee upon the exercise of awards under the Issuer's 2004 Stock Incentive Plan.
- [F5]The option vests with respect to 1/48 of the shares subject thereto on each monthly anniversary of the date of grant, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.